Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axonics Inc (NQ: AXNX )

70.98 UNCHANGED
Last Price Updated: 4:00 PM EST, Nov 14, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 0
Open 70.98
Bid (Size) 70.96 (9)
Ask (Size) 71.00 (40)
Prev. Close 70.98
Today's Range 70.98 - 70.98
52wk Range 55.09 - 70.98
Shares Outstanding 46,134,513
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Axonics Reports Third Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Axonics Receives Regulatory Approval for Fourth-Generation Rechargeable SNM System in Australia
From Axonics, Inc.
Via Business Wire

Performance

YTD
+18.87%
+18.87%
1 Month
+1.01%
+1.01%
3 Month
+2.94%
+2.94%
6 Month
+5.59%
+5.59%
1 Year
+24.90%
+24.90%

More News

Read More
Axonics Prevails in Patent Infringement Lawsuit with Medtronic
From Axonics, Inc.
Via Business Wire
Axonics Reports Second Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Beyond The Numbers: 7 Analysts Discuss Axonics Stock
Via Benzinga
Analyst Scoreboard: 5 Ratings For Axonics
Via Benzinga
7 Robotics Stocks That Could Grow Your Wealth
Via InvestorPlace
Axonics Receives Regulatory Approval for Recharge-Free SNM System in Australia
From Axonics, Inc.
Via Business Wire
AXNX Stock Earnings: Axonics Misses EPS, Beats Revenue for Q1 2024
Via InvestorPlace
Axonics Reports First Quarter 2024 Financial Results
From Axonics, Inc.
Via Business Wire
Why Axonics Stock Soared Today
Via The Motley Fool
Boston Scientific Bucks the Medtech Slow Down and Raises Outlook
Via MarketBeat
FDA Classifies Boston Scientific's Recall For Device To Stop Blood Flow As 'Most Serious'
Via Benzinga
Exposures Product Safety
Axonics Stockholders Approve Merger Agreement with Boston Scientific
From Axonics, Inc.
Via Business Wire
Axonics Receives CE Mark Approval for Fourth-Generation Rechargeable Sacral Neuromodulation System
From Axonics, Inc.
Via Business Wire
Axonics Responds to ITC Action by Medtronic
From Axonics, Inc.
Via Business Wire
Axonics Reports Fourth Quarter and Fiscal Year 2023 Financial Results
From Axonics, Inc.
Via Business Wire
AXONICS INVESTOR ALERT by the Former Attorney General of Louisiana: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Axonics, Inc. - AXNX
From Kahn Swick & Foti, LLC
Via Business Wire
Why Medical Devices Giant Boston Scientific Shares Are Rising Today
Via Benzinga
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Stock Market Rally Rebounds; Nvidia, Tesla, JPMorgan, Bitcoin ETFs In Focus: Weekly Review
Via Investor's Business Daily
Topics ETFs
Robinhood, Palo Alto Networks And 2 Other Stocks Insiders Are Selling
Via Benzinga
10 Top Stocks With a Strong Buy Rating Right Now
Via InvestorPlace
BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Ambrx Biopharma, Inc. (Nasdaq – AMAM), Gracell Biotechnologies Inc. (Nasdaq – GRCL), Axonics, Inc. (Nasdaq - AXNX), Harpoon Therapeutics, Inc. (Nasdaq - HARP)
From Brodsky & Smith LLC
Via GlobeNewswire
Why RxSight Shares Are Trading Higher By 20%? Here Are Other Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.